6-(pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-pyridine-2-carbonitrile | 913830-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-pyridine-2-carbonitrile
• 英文别名: 6-(Pyridin-3-yl-[1,2,4]oxadiazol-5-yl)pyridine-2-carbonitrile；6-(3-pyridin-3-yl-1,2,4-oxadiazol-5-yl)pyridine-2-carbonitrile
• CAS: 913830-22-5
• 化学式: C₁₃H₇N₅O
• 分子量: 249.231
• InChiKey: WXCZEZVPNSMKOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  507.3±60.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-bromo-6-(3-pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-pyridine 、 氰化钾 在 tris-(dibenzylideneacetone)dipalladium(0) 、 1,1'-bis(diphenylphosphino)ferrocene 三丁基氯化锡 作用下， 以 正庚烷 、 乙腈 为溶剂， 反应 17.5h， 生成 6-(pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-pyridine-2-carbonitrile
  参考文献：
  名称：

  WO2006/114400

  摘要：

  公开号：

文献信息

• Novel oxadiazole derivatives and their medical use
  申请人：Dahl Bjarne H.

  公开号：US20090312347A1

  公开（公告）日：2009-12-17

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的噁唑烷衍生物，其被发现是尼古丁乙酰胆碱受体的调节剂。由于其药理学特性，本发明中的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或疾患、内分泌疾病或疾患、神经退行性疾病或疾患、炎症、疼痛以及由于滥用化学物质而引起的戒断症状等疾病或疾患具有用处。
• NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE
  申请人：DAHL Bjarne H.

  公开号：US20110294856A1

  公开（公告）日：2011-12-01

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的噁唑啉衍生物，其被发现是乙酰胆碱受体的调节剂。由于它们的药理特性，该发明中的化合物可能有用于治疗各种与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病或紊乱、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状相关的疾病或紊乱。
• PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER
  申请人：Olsen Gunnar M.

  公开号：US20100234349A1

  公开（公告）日：2010-09-16

  This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.

  本发明涉及一种新型药物组合物，包括治疗有效的尼古丁受体正向变构调节剂和从以下组中选择的认知增强剂：尼古丁乙酰胆碱受体激动剂、乙酰胆碱酯酶抑制剂、正向AMPA受体调节剂、抗精神病药物、抗抑郁药物和抗帕金森药物。本发明的药物组合物特别适用于对抗认知障碍。
• Oxadiazole derivatives and their medical use
  申请人：Neurosearch A/S

  公开号：US08017631B2

  公开（公告）日：2011-09-13

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型氧化二唑衍生物，发现它们是尼古丁酸乙酰胆碱受体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）和外周神经系统（PNS）的胆碱能系统相关的疾病或障碍、平滑肌收缩相关的疾病或障碍、内分泌疾病或障碍、神经退行性疾病或障碍、炎症相关的疾病或障碍、疼痛和因滥用化学物质而引起的戒断症状可能有用。
• Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
  申请人：NeuroSearch AS

  公开号：EP2255848A2

  公开（公告）日：2010-12-01

  This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.

  本发明涉及新型药物组合物，其中包含尼古丁受体正性异位调节剂与认知增强剂的治疗有效组合，认知增强剂选自尼古丁乙酰胆碱受体激动剂、乙酰胆碱酯酶抑制剂、AMPA受体正性调节剂、抗精神病药物、抗抑郁药物和抗帕金森药物组成的组。根据本发明使用的药物组合物尤其适用于防治认知障碍。